How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States
Research output: Contribution to journal › Journal article › Research › peer-review
Views vary about how to avoid nephrogenic systemic fibrosis (NSF). In Europe, it is contraindicated to use gadodiamide, gadopentetate dimeglumine, and gadovertisamide in patients who have a glomerular filtration rate (GFR) of less than 30 mL/min, and these agents may only be used with caution in patients who have a GFR between 30 and 60 mL/min. Similar restrictions have not been introduced for the other six gadolinium-based contrast agents available in the European market. In the United States, the US Food and Drug Administration introduced a class ban and warned about the use of gadolinium-based contrast agents in patients who have reduced renal function. However, European and American guidelines about how to avoid NSF are generally not very different.
Original language | English |
---|---|
Journal | Radiologic Clinics of North America |
Volume | 47 |
Issue number | 5 |
Pages (from-to) | 871-5, vii |
Number of pages | 5 |
ISSN | 0033-8389 |
DOIs | |
Publication status | Published - 2009 |
Bibliographical note
Keywords: Contrast Media; Europe; Gadolinium; Humans; Kidney Function Tests; Nephrogenic Fibrosing Dermopathy; Practice Guidelines as Topic; Risk Factors; United States
ID: 20621326